Skip to main content

Advertisement

Log in

Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association

  • Hypertension and the Kidney (RM Carey, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Uric acid is the final oxidation product of purine metabolism in circulation and has been associated with the occurrence of gout and kidney stones. Type 2 diabetes mellitus and hypertension are two important public health challenges, and both are linked to increased risk of cardiovascular events. Hyperuricemia has recently emerged as an independent risk factor in the development of type 2 diabetes mellitus and hypertension through several proposed mechanisms. Few clinical trials investigated the use of uric acid lowering agents in the management of these two disease entities; however, their results provided encouraging evidence to a potential role for these agents in fighting disease burden. Larger randomized controlled trials are therefore warranted to establish the role of uric acid as a promising target for novel therapeutic interventions in the management of type 2 diabetes mellitus and hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Rock KL, Kataoka H, Lai J-J. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9(1):13–23.

    Article  CAS  PubMed  Google Scholar 

  2. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4:12.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Aung T, Myung G, FitzGerald JD. Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence. 2017;11:795–800.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kuwabara M. Hyperuricemia, cardiovascular disease, and hypertension. Pulse. 2016;3(3–4):242–52.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mortada I. Hyperbilirubinemia, hypertension, and CKD: the links. Curr Hypertens Rep. 2017;19(7):58. https://doi.org/10.1007/s11906-017-0756-8

  6. Pradeepa R, Mohan V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation. Eur J Clin Nutr. 2017;71(7):816–24.

    Article  CAS  PubMed  Google Scholar 

  7. Wang C, et al. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One. 2012;7(6):e38285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9(1):13–23.

    Article  CAS  PubMed  Google Scholar 

  9. • Jalal DI, et al. Uric acid as a target of therapy in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013;61(1):134–46. A review focusing on uric acid as a potential therapeutic target to prevent kidney disease onset and progression.

    Article  CAS  Google Scholar 

  10. Maiuolo J, et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14.

    Article  PubMed  Google Scholar 

  11. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–71.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Liote F. Hyperuricemia and gout. Curr Rheumatol Rep. 2003;5(3):227–34.

    Article  PubMed  Google Scholar 

  13. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–71.

    Article  PubMed  PubMed Central  Google Scholar 

  14. McDonagh EM, et al. PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics. 2014;24(9):464–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mende C. Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy. Adv Ther. 2015;32:1177–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6(1):30–8.

    Article  CAS  PubMed  Google Scholar 

  17. •• Li L, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122. This systematic review and meta-analysis shows that elevated serum uric acid levels showed an increased risk for the development of chronic renal dysfunction.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lapi F, et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ : British Medical Journal. 2013;346:e8525.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhu J-N, et al. Dietary factors associated with hyperuricemia and glycolipid metabolism disorder in middle-aged and elderly people. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2016;47(1):68–72.

    PubMed  Google Scholar 

  20. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.

    Article  PubMed  Google Scholar 

  21. Anton FM, et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35(4):343–8.

    Article  CAS  PubMed  Google Scholar 

  22. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the Third National Health and Nutrition Examination Survey. Arthritis Res Ther. 2008;10(5):R116.

    Article  PubMed  PubMed Central  Google Scholar 

  23. •• Lv Q, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One. 2013;8(2):e56864. This meta-analysis of prospective cohort studies provides strong evidence that high level of serum uric acid is independent of other established risk factors, for developing type 2 diabetes in middle-aged and older people.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Jia Z, et al. Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: a meta-analysis of cohort studies. Diabetes Res Clin Pract. 2013;101(1):88–96.

    Article  CAS  PubMed  Google Scholar 

  25. Kim SC, Liu J, Solomon DH. Risk of incident diabetes in patients with gout: a cohort study. Arthritis & rheumatology (Hoboken, NJ). 2015;67(1):273–80.

    Article  Google Scholar 

  26. Liu Y, et al. Serum uric acid levels and the risk of impaired fasting glucose: a prospective study in adults of north China. PLoS One. 2013;8(12):e84712.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lee S-H, Kim K-M, Kim K-N. Combined effect of serum gamma-glutamyltransferase and uric acid on incidence of diabetes mellitus: a longitudinal study. Medicine. 2017;96(19):e6901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Krishnan E, et al. Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM: An International Journal of Medicine. 2013;106(8):721–9.

    Article  CAS  Google Scholar 

  29. Maahs DM, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013;13(4):550–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chaudhary K, et al. Uric acid—key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3(3):208–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Matsuoka T, et al. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Investig. 1997;99(1):144–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Liu P, et al. The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study. Intern Med. 2015;54(17):2129–37.

    Article  CAS  PubMed  Google Scholar 

  33. Takir M, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. J Investig Med. 2015;63(8):924–9.

    Article  CAS  PubMed  Google Scholar 

  34. El-Bassossy HM, et al. Ameliorative effect of allopurinol on vascular complications of insulin resistance. Journal of Diabetes Research. 2015;2015:10.

    Article  Google Scholar 

  35. •• Grayson PC, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102–10. This systematic review and meta-analysis show that hyperuricemia is associated with an increased risk for incident hypertension, independent of traditional hypertension risk factors.

    Article  CAS  Google Scholar 

  36. Komendarek-Kowalska M. The assessment of renal function in patients with newly diagnosed hypertension—the role of hyperuricemia as a risk factor for chronic kidney disease—preliminary study. Pol Merkur Lekarski. 2017;42(251):193–6.

    PubMed  Google Scholar 

  37. Perlstein TS, et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–6.

    Article  CAS  PubMed  Google Scholar 

  38. Cicero AF, et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57–64.

    Article  CAS  PubMed  Google Scholar 

  39. • Mazzali M, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–6. The study reveals that elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.

    Article  CAS  PubMed  Google Scholar 

  40. Yu MA, et al. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28(6):1234–42.

    PubMed  Google Scholar 

  41. •• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32. This randomized trial shows that treatment with allopurinol reduces blood pressure in adolescents with newly diagnosed hypertension.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148–56.

    Article  CAS  PubMed  Google Scholar 

  43. •• Kanbay M, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33. This study brings indirect evidence that management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ibrahim Mortada.

Ethics declarations

Conflict of Interest

Dr. Mortada declares no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension and the Kidney

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mortada, I. Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association. Curr Hypertens Rep 19, 69 (2017). https://doi.org/10.1007/s11906-017-0770-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-017-0770-x

Keywords

Navigation